{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:05:06Z","timestamp":1761516306903,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.4158\/ep15936.or","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T15:41:52Z","timestamp":1450453312000},"page":"523-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["An Open-Label Extension Study of Parathyroid Hormone Rhpth(1-84) in Adults with Hypoparathyroidism"],"prefix":"10.1016","volume":"22","author":[{"given":"Peter","family":"Lakatos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Bajnok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hjalmar","family":"Lagast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Valkusz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP15936.OR_bb0010","unstructured":"National Organization for Rare Disorders. Hypoparathyroidism. Available at: http:\/\/www.rarediseases.org\/rare-disease-information\/rare-diseases\/byID\/703\/viewAbstract Accessed May 7, 2015."},{"key":"10.4158\/EP15936.OR_bb0015","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.4158\/EP15936.OR_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP10302.RA","article-title":"Medical management of postsurgical hypoparathyroidism","volume":"17","author":"Khan","year":"2011","journal-title":"Endocr Pract"},{"key":"10.4158\/EP15936.OR_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP15936.OR_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP15936.OR_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15936.OR_bb0040","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15936.OR_bb0045","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Hypoparathyroid Study Group","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15936.OR_bb0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001980070088","article-title":"Clinical use of biochemical markers of bone remodeling: current status and future directions","volume":"11","author":"Looker","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP15936.OR_bb0055","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15936.OR_bb0060","unstructured":"BilezikianJP, VokesT, RothmanJ, et al. Changes in bone turnover markers and bone mineral density with recombinant human parathyroid hormone, rhPTH(1-84), in hypoparathyroidism: potential utility as surrogate endpoints for monitoring\u2014the REPLACE study. Presented at: The American Society for Bone and Mineral Research: Annual Meeting; October 4\u20137, 2013; Baltimore, MD."},{"key":"10.4158\/EP15936.OR_bb0065","doi-asserted-by":"crossref","unstructured":"BilezikianJP, MaruaniG, RothmanJ, et al. Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1-84), on skeletal dynamics in hypoparathyroidism: findings from the 24-Week REPLACE and 8-week RELAY phase III clinical trials. Presented at: European Calcified Tissue Society Annual Meeting; May 17\u201320, 2014; Prague, Czech Republic.","DOI":"10.1530\/boneabs.3.PP92"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20392314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20392314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:00:48Z","timestamp":1761516048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20392314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1530891X20392314"],"URL":"https:\/\/doi.org\/10.4158\/ep15936.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Open-Label Extension Study of Parathyroid Hormone Rhpth(1-84) in Adults with Hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP15936.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}